The utility of aminoglycosides in an era of emerging drug resistance

International Journal of Antimicrobial Agents

Volumn 10, Issue 2, 1998, Pages 95-105

  Zembower, Teresa R ^a,b   Noskin, Gary A ^a,b   Postelnick, Michael J ^c   Nguyen, Chieu ^c   Peterson, Lance R ^a,b  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b NW Mem H   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Aminoglycoside; Antibiotic; Antimicrobial drug resistance; Nosocomial infection; Synergy

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; DIBEKACIN; GENTAMICIN; HABEKACIN; ISEPAMICIN; KANAMYCIN; NEOMYCIN; NETILMICIN; PAROMOMYCIN; SISOMICIN; SPECTINOMYCIN; STREPTOMYCIN; TOBRAMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; DRUG DEGRADATION; DRUG EFFICACY; DRUG INDICATION; DRUG INFORMATION; DRUG SENSITIVITY; ENTEROBACTERIACEAE; ESCHERICHIA COLI; FRANCISELLA TULARENSIS; GRAM NEGATIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; NEPHROTOXICITY; OTOTOXICITY; PRESCRIPTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SERRATIA; URINARY TRACT INFECTION; YERSINIA PESTIS;

EID: 0031853330     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(98)00033-8     Document Type: Review

References (73)

1. Schatz A, Bugie E, Waksman SA Streptomycin, a substance exhibiting antibiotic activity against gram positive and gram negative bacteria. Proc Soc Exp Biol Med. 55:1944;66.
2. Carbon C, Collatz E, Humbert G Aminoglycosides (aminocyclitols). Peterson PK, Verhoef J Antimicrobial Agents Annual I. 1986;1-16 Elsevier Science, Amsterdam.
3. Janknegt R. Aminoglycoside therapy: current use and future prospects. Pharm Weekbl Sci. 12:1990;81-90.
4. Spelman DW, McDonald M, Spicer WJ Aminoglycoside antibiotic agents: a review. Therapeutics. 151:1989;346-349.
5. Price KE Aminoglycoside research 1975-1985: prospects for development of improved agents. Antimicrob Agents Chemother. 29:1986;543-548.
6. Acar JF, Goldstein FW, Menard R, Bleriot J Strategies in aminoglycoside use and impact upon resistance. Am J Med. 80((suppl 6B)):1986;82-87.
7. Ristuccia AM, Cunha BA The aminoglycosides. Med Clin North Am. 66:1982;303-312.
8. Gerding DN, Larson TA, Hughes RA, Weiler M., Shanholtzer C, Peterson LR Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital. Antimicrob Agents Chemother. 35:1991;1284-1290.
9. Miller GH, Sabatelli FJ, Hare RS et al. The most frequent aminoglycoside resistance mechanisms-changes with time and geographic area: a reflection of aminoglycoside usage patterns? Clin Infect Dis. 24((suppl 1)):1997;S46-S62.
10. Begg EJ, Barclay ML Aminoglycosides - 50 years on. Br J Clin Pharmacol. 39:1995;597-603.
11. Smith H, editor. Antibiotics in Clinical Practice. Baltimore: University Park Press, 1977.
12. Okuda T, Ito Y. Biosynthesis and mutasynthesis of aminoglycoside antibiotics. In: Umezawa H, Hooper IR, editors. Aminoglycoside Antibiotics. Berlin: Springer-Verlag 1982, pp. 111-204.
13. Gilbert DN Aminoglycosides. Mandell GL, Bennett JE, Dolin R Principles and Practice of Infectious Diseases. fourth ed. 1995;279-306 Churchill Livingstone, New York.
14. Kondo S Development of arbekacin and synthesis of new derivatives stable to enzymatic modifications by methicillin-resistant Staphylococcus aureus. Jpn J Antibiotic. 47:1994;561-574.
15. Hamilton-Miller JM, Shah S Activity of the semi-synthetic kanamycin B derivative, arbekacin against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 35:1995;865-868.
16. Davies JE Aminoglycoside-aminocyclitol antibiotics and their modifying enzymes. Lorian V Antibiotics in Laboratory Medicine. 1986;790-809 Williams and Wilkins, Baltimore.
17. Sande MA, Mandell GL Antimicrobial agents: the aminoglycosides. Goodman Gilman A, Rall TW, Nies AS, Taylor P The Pharmacologic Basis of Therapeutics. 1990;1098-1116 Pergamon Press, New York.
18. Humbert G, Carbon C, Collatz E Aminoglycosides (aminocyclitols). Peterson PK, Verhoef J Antimicrobial Agents Annual 3. 1988;1-14 Elsevier Science, Amsterdam.
19. Davis B.D. The lethal action of aminoglycosides. J Antimicrob Chemother. 22:1988;1-3.
20. Siegenthaler WE, Bonetti A, Luthy R Aminoglycoside antibiotics in infectious diseases. Am J Med. 80((suppl 6B)):1986;2-14.
21. Neu HC Aminoglycosides: do we need new agents? Drugs. 12:1976;161-165.
22. Gregory D, Hirschmann JV Prudent use of the aminoglycosides. Postgrad Med. 64:1978;97-103.
23. Geller RJ, Norris SM The pharmacology of aminoglycosides: distinctions among the agents. Infect. Control. 5:1984;298-302.
24. Waldvogel FA Future perspectives of aminoglycoside therapy. J Antimicrob Chemother. 13((suppl A)):1984;73-78.
25. Young LS, Meyer-Dudnik DV, Hindler J, Martin WJ Aminoglycosides in the treatment of bacteraemic infections in the immunocompromised host. J Antimicrob Chemother. 8((suppl A)):1981;121-132.
26. Gaya H. Combination therapy and monotherapy in the treatment of severe infection in the immunocompromised host. Am J Med. 80((suppl 6B)):1986;149-155.
27. Zinner SH, Dudley M In vitro models for the study of combination antibiotic therapy in neutropenic patients. Am J Med. 80((suppl 6B)):1986;156-160.
28. Krogstad DJ, Moellering RC Antimicrobial combinations. Lorian V Antibiotics in Laboratory Medicine. 1986;537-599 Williams and Wilkins, Baltimore.
29. Michéa-Hamzehpour M, Pechère J, Marchou B, Auckenthaler R Combination therapy: a way to limit emergence of resistance? Am J Med. 80((suppl 6B)):1986;138-142.
30. Giamerllou H Aminoglycosides plus beta-lactams against gram-negative organisms. Am J Med. 80((suppl 6B)):1986;126-137.
31. Lerner SA, Dudek EJ, Boisvert WE, Berndt KD Effect of highly potent antipseudomonal beta-lactam agents alone and in combination with aminoglycosides against Pseudomonas aeruginosa. Rev Infect Dis. 6((suppl 3)):1984;S678-S688.
32. Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med. 87:1989;540-546.
33. Fish DN, Piscitelli SC, Danziger LH Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy. 15:1995;279-291.
34. Karchmer AW Cephalosporins. Mandell GL, Bennett JE, Dolin R Principles and Practice of Infectious Diseases. fourth ed. 1995;247-264 Churchill Livingstone, New York.
35. Leibovici L, Paul M, Poznanski O et al. Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective observational study. Antimicrob Agents Chemother. 41:1997;1127-1133.
36. Nichols RL Management of intra-abdominal sepsis. Am J Med. 80((suppl 6B)):1986;204-209.
37. Stone HH, Kolb LD, Geheber CE, Dawkins J Use of aminoglycosides in surgical infections. Ann Surg. 183:1976;660-666.
38. Ledger WJ Aminoglycosides in gynecologic infections. Am J Med. 80((suppl 6B)):1986;216-221.
39. Dworzack DL Aminoglycosides: mechanisms of action and resistance. Barnes WG, Hodges GR The Aminoglycoside Antibiotics: A Guide to Therapy. 1984;23-44 CRC Press, Boca Raton.
40. Mulazimoglu L, Drenning SD, Muder RR Vancomycin-gentamicin synergism revisited: effect of gentamicin susceptibility of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 40:1996;1534-1535.
41. Houlihan HH, Mercier R, Rybak MJ Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model. Antimicrob Agents Chemother. 41:1997;2497-2501.
42. Watanakunakorn C, Tisone JC Synergism between vancomycin and gentamicin or tobramycin for methicillin-susceptible or methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother. 22:1982;903-905.
43. Alford RH Saturday conference: a clinician looks at the aminoglycoside antibiotics. South Med J. 71:1978;684-693.
44. Schlegel L, Sissia G, Fremaux A, Geslin P. In-vitro killing activity of combinations of beta-lactam agents with aminoglycosides against penicillin-resistant pneumococci. J Antimicrob Chemother. 39:1997;95-98.
45. Sanders CC, Sanders WE Resistance to antimicrobial agents. Jungkind DL Antimicrobial Resistance: A Crisis in Health Care. 1995;15-23 Plenum Press, New York.
46. Dowding JE Mechanisms of gentamicin resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 11:1977;47-50.
47. Van Landuyt HW, Boelaert J, Glibert B, Gordts B, Verbruggen A Surveillance of aminoglycoside resistance. Am J Med. 80((suppl 6B)):1986;76-81.
48. Ruiz-Palacios GM, Ponce de Leon S, Sifuentes J et al. Control of emergence of multi-resistant gram-negative bacilli by exclusive use of amikacin. Am J Med. 80((suppl 6B)):1986;71-75.
49. Phillips I, King A, Shannon K Prevalence and mechanisms of aminoglycoside resistance. Am J Med. 80((suppl 6B)):1986;48-55.
50. Young LS, Hindler J Aminoglycoside resistance: a worldwide perspective. Am J Med. 80((suppl 6B)):1986;15-21.
51. Moellering RC, Wennersten C, Kunz LJ, Poitras JW Resistance to gentamicin, tobramycin, and amikacin among clinical isolates of bacteria. Am J Med. 62:1977;873-881.
52. Davies, J, Courvalin, P. Mechanisms of resistance to aminoglycosides. Am J Med 1977;25-29.
53. Mayer KH Review of epidemic aminoglycoside resistance worldwide. Am J Med. 80((suppl 6B)):1986;56-64.
54. Bailey TC, Little JR, Littenberg B, Reichley RM, Dunagan WC A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis. 24:1997;786-795.
55. Ali MZ, Goetz MB A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis. 24:1997;796-809.
56. Hatala R, Dinh TT, Cook DJ Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review. Clin Infect Dis. 24:1997;810-815.
57. Gilbert DN Editorial response: meta-analyses are no longer required for determining the efficacy of single daily dosing of aminoglycosides. Clin Infect Dis. 2:1997;816-819.
58. Bertino JS, Rotshafer JC Editorial response: single daily dosing of aminoglycosides - a concept whose time has not yet come. Clin Infect Dis. 24:1997;820-823.
59. Nicolau DP, Freeman CD, Belluveau PP., Nightingale CH, Ross JW, Quintilliani R Experience with a once-daily aminoglycoside program administered to 2184 adult patients. Antimicrob Agents Chemother. 39:1995;650-655.
60. Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother. 39:1997;677-686.
61. Nordström L, Ringberg H, Cronberg S, Tjernström O, Walder M Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity? J Antimicrob Chemother. 25:1990;159-173.
62. Begg EJ, Barclay ML, Duffull SB A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol. 39:1995;605-609.
63. Blaser J, König C Once-daily dosing of aminoglycosides. Eur J Clin Microbiol Infect Dis. 14:1995;1029-1038.
64. Okpara AU, Amaya-Diaz A, Egbunike IG, Maswoswe JJ, Enigbokan MA Evaluating once daily dosing of aminoglycosides: an observational study. Formulary. 31:1996;34-48.
65. Gilbert DN Once-daily aminoglycoside therapy. Antimicrob Agents Chemother. 35:1991;399-405.
66. Zembower TR, Nguyen C, Postelnick M, Noskin GA. Once-daily dosing of aminoglycosides is efficacious and more cost effective compared to conventional dosing. In: Programs and Abstracts of the Infectious Diseases Society of America 34th Annual Meeting, New Orleans, LA 1996; (Abstract 295).
67. Eisenberg JM, Koffer H, Glick HA et al. What is the cost of nephrotoxicity associated with aminoglycosides? Ann Intern Med. 107:1987;900-909.
68. Sethi K, Diamond LH Aminoglycoside nephrotoxicity and its predictability. Nephron. 27:1981;265-270.
69. Federspil P, Schatzle W, Tiesler E Pharmacokinetics and ototoxicity of gentamicin, tobramycin, and amikacin. J Infect Dis. 134 (suppl):1976;S200-S205.
70. Fong IW, Fenton RS, Bird R Comparative toxicity of gentamicin versus tobramycin: a randomized prospective study. J Antimicrob Chemother. 7:1981;81-88.
71. Kahlmeter G, Dahlager JI Aminoglycoside toxicity-a review of clinical studies published between 1975-1982. J Antimicrob Chemother. 13((suppl A)):1984;9-22.
72. Mattie H, Craig WA, Pechère JC Determinants of efficacy and toxicity of aminoglycosides. J Antimicrob Chemother. 24:1989;281-293.
73. Feig PU, Mitchell PP, Abrutyn E et al. Aminoglycoside nephrotoxicity: a double blind prospective randomized study of gentamicin and tobramycin. J Antimicrob Chemother. 10:1982;217-226.